Nicox S.A. (OTCMKTS:NICXF – Free Report) – Investment analysts at HC Wainwright lowered their Q1 2024 earnings per share estimates for shares of Nicox in a research report issued to clients and investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.03) for the quarter, down from their prior forecast of ($0.02). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q3 2024 earnings at ($0.07) EPS.
Nicox Stock Performance
OTCMKTS:NICXF opened at $0.44 on Thursday. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.52. Nicox has a 52-week low of $0.44 and a 52-week high of $0.44.
About Nicox
Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Further Reading
- Five stocks we like better than Nicox
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Nucor Stock Earnings Riding the Steel Industry Wave
- How is Compound Interest Calculated?
- Simpson Manufacturing: Buy This Future Dividend King While Down
- Most active stocks: Dollar volume vs share volume
- Is Boeing Stock About to Soar Higher?
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
